Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis drops bid for Berna

January 16, 2006 | A version of this story appeared in Volume 84, Issue 3

Novartis has bowed out of the race for Swiss vaccine maker Berna Biotech after completing due diligence. Novartis' exit paves the way for an acquisition of Berna by the Dutch firm Crucell, which in November offered to buy Berna in a share exchange valued at roughly $450 million. That exchange was expected to begin in mid-December, but Novartis stepped in at the last hour to evaluate a cash bid for Berna. Last week, Crucell shareholders approved the offer for Berna. Analysts say Novartis' decision could signal its interest in Swiss biotech major Serono, which in November hired Goldman Sachs to explore strategic alternatives.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.